Catalyst Event
Livzon Pharmaceutical Group Inc (1513) · Other
From Akros SCHK HK-Global Genomics Index (ASHGGENM)
6/1/2026, 12:00:00 AM
Announced on 2026-06-01 that the marketing application for Laikangqita monoclonal antibody injection was accepted for review by China's NMPA. Medium importance as a key drug development milestone.
Korean Translation
2026년 6월 1일 강직성 척추염 치료제 '라이캉치타' 단일클론항체 주사제의 중국 NMPA 판매 허가 신청 접수 발표함. 주요 신약 개발 마일스톤 달성으로 중요도를 중간으로 평가함.
Related Recent Events
Pacific Biosciences of California Inc (PACB) · Earnings Release
Q2 2026 earnings release is scheduled.
8/6/2026, 12:00:00 AM
Pharmaron Beijing Co Ltd (3759) · Other
The ex-dividend date for the RMB 0.20 per share final dividend on July 7, 2026, with payment on August 7, 2026; market reaction is estimated at Low as the payout is within expected ranges scheduled.
7/7/2026, 12:00:00 AM
Jinxin Fertility Group Limited (1951) · Other
Ex-dividend date on 2026-06-29 for the 2025 final dividend of HK$0.0418 per share; Low importance justified by it being a standard technical adjustment scheduled
6/29/2026, 12:00:00 AM
Hansoh Pharmaceutical Group Company Limited (3692) · Other
Annual General Meeting on June 26, 2026, to approve 2025 results and dividends. Analysts estimate a 1-5% price impact for this routine corporate event scheduled.
6/26/2026, 12:00:00 AM
Jinxin Fertility Group Limited (1951) · Other
Annual General Meeting on 2026-06-25 to vote on 2025 financial statements and a HK$0.0418 dividend; Low importance justified by the routine nature of the meeting scheduled
6/25/2026, 12:00:00 AM
Biocytogen Pharmaceuticals (Beijing) Co Ltd (2315) · Other
An extraordinary general meeting is scheduled on 2026-06-25 to vote on a new executive remuneration system and a 10% H-share repurchase mandate; 1% price impact expected.
6/25/2026, 12:00:00 AM